Which drug classification does resmetirom belong to?

Resmetirom-Rezdiffra is a new selective thyroid hormone receptor beta (THR-β) agonist. It was originally developed to target non-alcoholic steatohepatitis (NASH) and its accompanying moderate to severe liver fibrosis, which has long plagued clinical practice.

Different from traditional hepatoprotective agents or drugs that simply improve metabolism, rismetirol is clearly classified as a "small molecule oral drug targeting metabolic pathways" in the drug classification and is a new generation of innovative metabolic regulation drugs. Its mechanism is to selectively activate thyroid hormone receptor β in the liver, promote lipid metabolism in liver cells, accelerate fat clearance, thereby reducing lipid deposition in the liver, thereby improving inflammation and fibrosis progression. Compared with the systemic effects related to thyroid hormones, the selectivity of rismetirol prevents interference with other tissues such as the heart and bones when regulating liver lipid metabolism. This is also the key to its classification and value.

In the treatment field, rismetirox is one of the first drugs approved for adultsNASH accompanied by stage F2 to F3 fibrosis. It represents that the field has truly entered a new stage of "drugs that can be cured". For a long time, NASH has been considered to be a concurrent manifestation of multiple chronic diseases such as metabolic syndrome, obesity, and type 2 diabetes. Its course is complex and the risk of developing cirrhosis and even liver cancer is extremely high. However, effective drug options have been lacking. The emergence of resmetirol has changed this situation and clarified its status in drug classification, that is, it is an innovative targeted small molecule drug for the treatment of metabolic liver diseases.

It is worth noting that resmetirol is not a single therapy. Its approved use requires that it be implemented in conjunction with a healthy diet and regular exercise. This is fully consistent with the current international concept of comprehensive intervention for metabolic liver disease. In other words, it is both a breakthrough point in drug treatment and a matching tool for lifestyle management.

Reference materials:https://www.drugs.com/monograph/resmetirom.html